NASDAQ:KYTX Kyverna Therapeutics (KYTX) Stock Price, News & Analysis $5.05 +0.02 (+0.40%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$5.26 +0.21 (+4.16%) As of 11/13/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Kyverna Therapeutics Stock (NASDAQ:KYTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kyverna Therapeutics alerts:Sign Up Key Stats Today's Range$4.82▼$5.5450-Day Range$4.61▼$8.2552-Week Range$4.49▼$13.67Volume834,189 shsAverage Volume827,804 shsMarket Capitalization$312.29 millionP/E RatioN/ADividend YieldN/APrice Target$29.00Consensus RatingModerate Buy Company Overview Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis. Founded in 2018 and based in Emeryville, California, Kyverna is focused on advancing its cell therapy candidates through clinical development.AI Generated. May Contain Errors. Read More Kyverna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreKYTX MarketRank™: 2.60334903192 of 5 starsKyverna Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 523rd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingKyverna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialKyverna Therapeutics has a consensus price target of $29.00, representing about 474.3% upside from its current price of $5.05.Amount of Analyst CoverageKyverna Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Kyverna Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($2.70) to ($2.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kyverna Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kyverna Therapeutics is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKyverna Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.85% of the float of Kyverna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKyverna Therapeutics has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in Kyverna Therapeutics has recently decreased by 4.69%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKyverna Therapeutics does not currently pay a dividend.Dividend GrowthKyverna Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.78 News SentimentKyverna Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Kyverna Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for KYTX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows4 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.60% of the stock of Kyverna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions18.08% of the stock of Kyverna Therapeutics is held by institutions.Read more about Kyverna Therapeutics' insider trading history. Receive KYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KYTX Stock News HeadlinesExecution Risks for Kyverna Therapeutics: Regulatory Hurdles and Delays in Autologous Cell Therapy DevelopmentNovember 13 at 1:10 AM | tipranks.comDid Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?November 12 at 12:12 PM | prnewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 14 at 1:00 AM | Weiss Ratings (Ad)Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial ResultsNovember 12 at 8:25 AM | finance.yahoo.comKyverna Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Kyverna Therapeutics, Inc. - KYTXNovember 11 at 1:32 PM | businesswire.comKyverna Therapeutics (KYTX) Set to Post Quarterly Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comKyverna Therapeutics Announces JAMA Neurology Publication of KYSA-8 Registrational Data for Mivocabtagene Autoleucel in Stiff Person SyndromeNovember 9, 2026 | quiverquant.comQKyverna Therapeutics Announces Publication of Registrational Miv-cel Data in Patients with Stiff Person Syndrome in JAMA NeurologyNovember 9, 2026 | globenewswire.comSee More Headlines KYTX Stock Analysis - Frequently Asked Questions How have KYTX shares performed this year? Kyverna Therapeutics' stock was trading at $9.40 at the beginning of 2026. Since then, KYTX stock has decreased by 46.3% and is now trading at $5.05. How were Kyverna Therapeutics' earnings last quarter? Kyverna Therapeutics, Inc. (NASDAQ:KYTX) issued its earnings results on Thursday, November, 12th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.01. When did Kyverna Therapeutics IPO? Kyverna Therapeutics (KYTX) raised $297 million in an initial public offering on Thursday, February 8th 2024. The company issued 14,500,000 shares at $20.00-$21.00 per share. Who are Kyverna Therapeutics' major shareholders? Kyverna Therapeutics' top institutional investors include AIGH Capital Management LLC (5.90%), State Street Corp (1.95%), Marshall Wace LLP (0.12%) and ACT Capital Partners L.P. (0.06%). Insiders that own company stock include Biopartners Opportuni Westlake, Beth C Seidenberg, Northpond Ventures Iii Gp, Llc and Karen Marie Walker. View institutional ownership trends. How do I buy shares of Kyverna Therapeutics? Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kyverna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), Cabaletta Bio (CABA), CrowdStrike (CRWD) and Intel (INTC). Company Calendar Last Earnings11/12/2026Today11/14/2026Jefferies Global Healthcare Conference11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 KYTX's financial health is in the Yellow zone, according to TradeSmith. KYTX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KYTX Previous SymbolNASDAQ:KYTX CIK1994702 Webkyvernatx.com Phone(510) 925-2492FaxN/AEmployees149Year Founded2018Price Target and Rating Average Price Target for Kyverna Therapeutics$29.00 High Price Target$33.00 Low Price Target$25.00 Potential Upside/Downside+474.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$161.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-79.77% Return on Assets-61.42% Debt Debt-to-Equity Ratio0.15 Current Ratio9.06 Quick Ratio9.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.85 per share Price / Book1.31Miscellaneous Outstanding Shares61,840,000Free Float50,959,000Market Cap$312.29 million OptionableOptionable Beta2.12 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:KYTX) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
